image credit- getty images
Palo Alto‑based PGxAI, a leader in AI-powered pharmacogenomics, and Saudi Arabia’s Novo Genomics are enabling safer, personalised prescribing to patients across the Kingdom.
The partners established an end-to-end workflow that spans local lab processing, AI-assisted analysis, and clinician-ready reporting. With Novo Genomics’ local laboratory infrastructure and PGxAI’s AI‑driven analytics, the initiative will shorten turnaround times, strengthen data governance, and expand access to precision medicine in the Kingdom’s health systems.
Patient participation is voluntary and consent-based, with insights shared in plain language to support clinicians in care planning. The programme focuses on medication safety, reducing adverse drug reactions, and ensuring equitable access, with education for patients, clinicians, and families across the Kingdom.
The collaboration complements PGxAI’s broader regional strategy with Najashi Holding to localise next‑generation precision‑health platforms in support of Saudi Arabia’s Vision 2030 and the Health Sector Transformation Program. Together, the organizations will pursue training, technology transfer, and research initiatives that build enduring expertise and position the Kingdom at the forefront of precision medicine.
As the partnership progresses, the parties plan to align on platform architecture, governance, and clinical pathways that can be deployed within leading institutions nationwide. The effort is expected to catalyse new research, enable role‑based decision support for providers, and establish a sustainable foundation for Saudi‑specific insights and innovation.
